Nephron

Original Paper

Effect of Cyclosporin Weaning on Glomerular Filtration Rate in Renal Transplantation

Salas M.c · Loertscher R.a · Caro J.J.b

Author affiliations

Departments of aNephrology and bMedicine, and cRoyal Victoria Hospital and Epidemiology Department, McGill University, Montreal, Que., Canada

Related Articles for ""

Nephron 1996;74:309-312

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Accepted: November 28, 1995
Published online: December 24, 2008
Issue release date: 1996

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0

ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)

For additional information: https://www.karger.com/NEF

Abstract

The objective of this study was to determine the effect of weaning cyclosporin on glomerular filtration rate in 55 renal transplant patients from the Renal Transplant Unit at the Royal Victoria Hospital. Men or women, older than 20 years of age, who received cadaveric or living-related renal transplant and who were treated with the complete cyclosporin protocol, were included. Weaning of cyclosporin was started 15 days after the prednisone dose was reduced to 15 mg/day and this weaning process was completed at day 105 posttransplant. The daily cyclosporin dose was decreased by 25 mg once every 2 weeks, and completely withdrawn after treatment when 50 mg/day was tolerated for 2 weeks. The duration of the weaning process varied because of fixed dose reduction. Renal graft function was assessed by plasma creatinine concentrations. We used the time point of cyclosporin discontinuation as time zero. Serum creatinine decreased over the time from 150 ± 61 mmol/l at time zero to 100 ± 18 mmol/l in the last determination, while GFR had a significant increment from 66 ± 18 to 77 ± 20. A total of 4 rejection episodes were observed 6 months after cyclosporin discontinuation. There were no graft failures and deaths. To determine predictors of improvement, we carried out multiple regression analysis and we found that prophylactic antilymphocyte globulin and the onset of graft function after transplantation were predictors.

© 1996 S. Karger AG, Basel




Related Articles:


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Accepted: November 28, 1995
Published online: December 24, 2008
Issue release date: 1996

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 0

ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)

For additional information: https://www.karger.com/NEF


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP